Table 1.
Clinical characteristics of patients with non-critically ill COVID-19.
| Characteristics | No. (%) |
|---|---|
| No. of patients | 1,682 |
| Age, median [IQR], (range), years | 50 [39–58], (5–89) |
| <30 | 125 (7.4) |
| 30–45 | 508 (30.2) |
| 46–65 | 892 (53.0) |
| ≥65 | 157 (9.3) |
| Gender | |
| Female | 859 (51.1) |
| Male | 823 (48.9) |
| From onset of symptom to hospital admission, median [IQR] (range), days | 10 (7–15), (1–60) |
| Hospital stay, median [IQR] (range), days | 19 (14–23), (1–29) |
| Comorbidities | |
| Hypertension | 118 (7.0) |
| Diabetes | 53 (3.2) |
| Lung disease | |
| Chronic bronchitis | 30 (1.8) |
| Bronchiectasis | 3 (0.2) |
| Tuberculosis | 3 (0.2) |
| Coronary heart disease | 15 (0.9) |
| Cerebral infarction | 5 (0.3) |
| Turning to nucleic acid negative, median [IQR] (range), days | 9 (5–13), (0–25) |
| Treatments | |
| Traditional Chinese Medicine (Qingfei Paidutang, QPD) | 1,617 (96.1) |
| Lianhua Qingwen capsule | 1,372 (81.4) |
| Antibiotics | 899 (53.4) |
| Moxifloxacin hydrochloride | 863 (51.3) |
| Cephalosporin | 103 (6.1) |
| Azithromycin | 12 (7.1) |
| Antivirals | 1,355 (80.6) |
| Umifenovir | 1,316 (78.2) |
| Lopinave/Litonawe (62, 3.7%) | 164 (9.8) |
| Oseltamivir | 62 (3.7) |
| Tenofovir | 2 (0.1) |
| Glucocorticoid (budesonide) | 2 (0.1) |
| Expansion of pulmonary infection | 114 (6.8) |
IQR, interquartile range; COVID-19, Coronavirus disease 2019. The results were presented as median [IQR] (range) for continuous variables and number (%) for categorical variables.